SCHEMBL6486899

SCHEMBL6486899

C(#Cc1nc2ccccc2[nH]1)CN1CCC2=C(CN(Cc3ccco3)C=N2)C1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.33
LMNA P02545 5/20 0.33
TSHR P16473 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
TPH2 Q8IWU9 1/20 0.33
HTR1A P08908 2/20 0.32
DRD2 P14416 2/20 0.32
HTR2A P28223 1/20 0.32
KDM4E B2RXH2 3/20 0.32
MAPK1 P28482 3/20 0.32
USP2 O75604 2/20 0.32
IDE P14735 2/20 0.32
MAPT P10636 2/20 0.32
HSD17B10 Q99714 2/20 0.32
ADRB2 P07550 1/20 0.32
HTR7 P34969 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6495545 0.87 HTT (0.42) ALDH1A1CYP3A4HTR1ADRD2KDM4E
SCHEMBL6488328 0.87 DRD4 (0.40) HTR1ADRD2MAPTHTR7HRH1
SCHEMBL6500590 0.87 DRD4 (0.33) ALDH1A1CYP3A4HTR1ADRD2KDM4E
SCHEMBL6498194 0.86 HTR2B (0.34) HTR1ADRD2HTR7HRH1DRD3
SCHEMBL6486470 0.85 LMNA (0.37) ALDH1A1LMNATSHRHTR1ADRD2
SCHEMBL6496243 0.84 DRD4 (0.43) HTR1ADRD2KDM4EMAPTHTR7
SCHEMBL6490571 0.84 DRD4 (0.35) ALDH1A1CYP3A4HTR1ADRD2KDM4E
SCHEMBL6485909 0.84 TP53 (0.33) TSHRHTR1ADRD2MAPK1MAPT
SCHEMBL6484988 0.84 DRD2 (0.32) ALDH1A1LMNAHTR1ADRD2MAPT
SCHEMBL6485453 0.84 DRD4 (0.37) ALDH1A1LMNATSHRHTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6869958-B2 Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-03-22 US disclosed
US-20040038960-A1 Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors LI JIE JACK (US) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038960-A1 Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors MMP9, MMP3, MMP13 ALDH1A1 1071/4885LMNA 3536/4885TSHR 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.